Servier introduces Tibsovo, the first targeted therapy for IDH1-Mutated cancers in Egypt

EGYPT—Servier Egypt has officially launched Tibsovo (ivosidenib), marking the introduction of the first targeted therapy in Egypt for patients diagnosed with IDH1-mutated Acute Myeloid Leukemia (AML) and intrahepatic cholangiocarcinoma.

The launch represents a significant advancement in precision oncology, offering new hope to patients who previously had limited treatment options.

According to clinical data released by the company, Tibsovo demonstrates a median overall survival of 29.3 months for eligible AML patients and 10.3 months for patients diagnosed with intrahepatic cholangiocarcinoma.

These outcomes highlight the drug’s therapeutic potential in managing two aggressive and hard-to-treat cancer types.

The treatment is approved as a first-line therapy for AML and as a second-line option for intrahepatic cholangiocarcinoma in individuals carrying the IDH1 gene mutation.

Tibsovo specifically targets the genetic driver that fuels tumour growth, allowing physicians to treat cancer at its molecular source rather than relying solely on conventional methods such as intensive chemotherapy or stem-cell transplantation.

This makes it an especially valuable option for patients who are unable to tolerate highly aggressive treatments.

“Bringing Tibsovo to Egypt is yet another step in Servier’s commitment to widening access to innovative treatments that address clear medical needs,” said Samy Sinnuqrut, General Manager of Servier Egypt.

“Our mission is to ensure that these medical advances reach patients in a reliable and timely way.”

Acute Myeloid Leukemia (AML) is a fast-progressing blood cancer that develops in the bone marrow and spreads rapidly if untreated. Intrahepatic cholangiocarcinoma, on the other hand, is a rare but serious cancer arising from the bile ducts inside the liver.

Both forms of cancer may be associated with IDH1 mutations, which alter how cells produce energy and grow uncontrollably.

According to Professor Ibtisam Saad El Din, an oncologist at Cairo University, the availability of Tibsovo offers doctors an important new option to tailor cancer therapy to each patient’s genetic profile.

She emphasized that early identification of the IDH1 mutation through routine genetic testing plays a vital role in determining the most effective treatment plan.

Clinical evidence supports the therapy’s efficacy. Results from the AGILE clinical trial reported improved event-free and overall survival rates among AML patients who were ineligible for intensive chemotherapy.

Similarly, the ClarIDHy study confirmed meaningful survival benefits and better disease control among patients with intrahepatic cholangiocarcinoma.

“Tibsovo provides a scientifically precise option with a more favourable tolerability profile for patients who cannot endure aggressive chemotherapy,” said Tamer El Nahas, Oncology Consultant and Professor at Cairo University.

Professor Gamal Fathy, a specialist in hematology and bone marrow transplantation at the Nasser Institute, added that the oral formulation of Tibsovo allows sustained clinical responses in AML patients and helps reduce dependence on repeated blood transfusions.

Servier Egypt highlighted that nearly 70% of the company’s global research and development investment focuses on oncology innovations.

The launch of Tibsovo aligns with international clinical guidelines, including recommendations from the National Comprehensive Cancer Network (NCCN) and the European Society for Medical Oncology (ESMO).